New clinical trials recently added to the National Cancer Institute's database
BRAIN/CNS TUMORS
Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy
Phase: Phase IV
Type: Supportive care, Treatment
Age: 19 and over
Trial IDs: OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568
BREAST CANCER
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7389-M001-218,
NCI-2015-01436, KEYNOTE-150, NCT02513472
Hypofractionated Regional Nodal Radiation Therapy in Treating Older Patients with Breast Cancer Who Have Undergone Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and over
Trial IDs: MCC-15-10994,
NCI-2015-01317, NCT02515110
Panitumumab, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Carboplatin in Treating Patients with HER2-Negative Primary Inflammatory Breast Cancer Receiving Combination Chemotherapy and Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2008-0372,
NCI-2012-00935, NCI-2010-02235, NCT01036087
Metformin Hydrochloride in Reducing Treatment-Related Neuropathy in Patients with Stage I-IV Breast Cancer Undergoing Treatment with Paclitaxel
Phase: Phase II
Type: Supportive care
Age: Over 18
Trial IDs: 2014-0438,
NCI-2015-00510, NCT02360059
Carboplatin and Docetaxel or Carboplatin and Paclitaxel Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with Stage I-III Triple-Negative Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2014-BRST-TNBC-LQT, NCI-2015-01416, STUDY00002467, NCT02413320
CERVICAL CANCER
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Stage IVB or Recurrent Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0625,
NCI-2015-00211, NCT02348398
COLORECTAL CANCER
A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BP29262,
NCI-2014-01282,
NCT02141295
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCRN GI14-186,
NCI-2015-01466,
NCT02375672
ENDOMETRIAL CANCER
Levonorgestrel-Releasing Intrauterine System with or without Everolimus in Treating Patients with Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0944,
NCI-2015-00919, NCT02397083
HEAD & NECK/ORAL CANCER
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 246513, NCI-2014-00756, NCT02119728
Surgery with or without Stereotactic Body Radiotherapy in Treating Patients with Previously-Irradiated Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-151, NCI-2015-01424, NCT02516969
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A5481044, NCI-2015-01296, 2015-000515-41, NCT02499120
Azacitidine in Measuring Tumor Response in Patients with HPV Positive or Negative Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1404013771,
NCI-2015-01437, 200 FR. 4 (2012-1), NCT02178072
LEUKEMIA/LYMPHOMA/MDS
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-016,
NCI-2013-00461, NCT01874054
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C34002, NCI-2015-00064, U1111-1163-2185, NCT02323113
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-19,
NCI-2015-01462,
NCT02391545
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521,
NCI-2015-00779, NCT02420717
Akt/ERK Inhibitor ONC201 in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, or Transformed Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0630, NCI-2015-00706, NCT02420795
Tocladesine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14269, NCI-2015-00871, 116608, 120003, NCT02509546
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus JNJ-56022473 (Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Phase: Phase II
Type: Treatment
Age: 65 and over
Trial IDs: CR107273, NCI-2015-01326, 56022473AML2002, NCT02472145
Meloxicam and Filgrastim in Collecting Peripheral Blood Stem Cells for Transplant in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: IUCRO-0419, NCI-2014-00470, NCT02078102
Augmented Berlin-Frankfurt-Munster Therapy and Ofatumumab in Treating Patients with B-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: 12 to 30
Trial IDs: 2014-0396, NCI-2015-00967, NCI-2010-01164, NCI-2012-01650, NCT02419469
Bendamustine Hydrochloride, Obinutuzumab, and Dexamethasone in Treating Older Patients with Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: IRB14-1120, NCI-2015-00355, NCT02420210
Pembrolizumab in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1485, NCI-2014-02561, Mod14-005666-04, NCT02332980
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SCRI CNS 20,
NCI-2015-01353, NCT02113007
Rituximab and Pembrolizumab in Treating Patients with Relapsed Follicular Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0539, NCI-2015-01307, Merck protocol - 3475-110, NCT02446457
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-Q, EAY131-R, EAY131-U, EAY131-V, NCT02465060
FLT PET/CT in Measuring Response in Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: EAI141,
NCI-2015-00328,
NCT02392429
Donor Hematopoietic Stem Cell Transplant and Combination Chemotherapy as Initial Salvage Therapy in Treating Patients with Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 2014-0358, NCI-2015-00849, NCT02441803
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CCTL019C2201, NCI-2015-01461, 2014-003060-20, NCT02445248
LUNG CANCER
Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients with Recurrent or Metastatic Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHI-80,
NCI-2015-01411, 9878,
NCT02535338
Selinexor and Docetaxel in Treating Patients with Recurrent or Metastatic Squamous Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14152, NCI-2015-01165, NCT02536495
Study Evaluating the Efficacy, Safety and Pharmacokinetics in Patient With T790M-positive Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: HM-EMSI-202, NCI-2015-01440, NCT02485652
MELANOMA
Interleukin-12 Gene Electroporation Therapy and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC #15852, NCI-2015-01300, 133438, 15852, NCT02493361
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0922, NCI-2015-01395, NCT02500576
MYELOMA
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 72
Trial IDs: 11-12-434,
NCI-2013-01207, 11-102, NCT01605032
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan before Stem Cell Transplant in Treating Patients with Refractory or Relapsed Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 2014-0516, NCI-2015-01308, NCT02506959
Sotatercept in Increasing Bone Mineral Density in Patients with Multiple Myeloma with Complete or Very Good Partial Response after Previous Treatment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: Over 18
Trial IDs: IUCRO-0428, NCI-2014-01967, 1408844060, ACE-011-MM-PI-0008, NCT02230917
OVARIAN CANCER
Chemoimmunotherapy and Vaccine Therapy in Treating Patients with Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 11-128, NCI-2015-00800, 11-128, NCT02432378
Dose Dense Paclitaxel with Pembrolizumab in Platinum Resistant Ovarian Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18207,
NCI-2015-01418, NCT02440425
MEDI4736 and Olaparib or Cediranib Maleate in Treating Patients with Advanced Solid Tumors or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0145, NCI-2015-01401, 344406, P141726, NCT02484404
PANCREATIC CANCER
Tosedostat and Capecitabine in Treating Patients with Pancreatic Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201503074,
NCI-2015-00425,
NCT02352831
Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-4350,
NCI-2015-01388, NCT02329717
Combination Chemotherapy in Treating Patients with Pancreatic Cancer before Undergoing Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: CASE4214,
NCI-2014-02277, NCT02345460
Regorafenib and Gemcitabine Hydrochloride as Second-Line Therapy in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE5214,
NCI-2015-00146,
NCT02383433
PROSTATE CANCER
Effects of Endocrine Therapy with or without Trametinib or Dasatinib in Patients with Localized, Untreated Prostate Cancer Undergoing Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB#13-000714,
NCI-2015-01448, EMT13001,
NCI-2014-02414,
NCT01990196
MISCELLANEOUS/MULTIPLE/OTHER
Brody Belt in Improving Quality of Life in Patients Using Urinary Drainage Bags
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: I 153209, NCI-2010-00339, NCT01228864
CD34-Positive Donor Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: 2015-0295,
NCI-2015-00979, NCT02438904
Chaplain-Led Counseling in Improving Quality of Life in Caregivers of Patients With Life-Limiting Illness
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00039370,
NCI-2014-00029,
NCT01768221
Cidofovir or Best Supportive Care in Treating BK Virus-Related Hemorrhagic Cystitis in Patients Previously Treated with Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: 6 and over
Trial IDs: 2010-0518,
NCI-2011-00250, NCT01295645
Clofarabine in Treating Patients with Recurrent or Refractory Langerhans Cell Histiocytosis
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 15-005, NCI-2015-00917, NCT02425904
Cognitive-Behavioral Weight Loss Program in Reducing Weight in Obese Women
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis
Age: 21 and over
Trial IDs: UCSD 20133218, NCI-2013-01966, 110876, NCT01424007
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Phase: No phase specified
Type: Tissue collection/Repository
Age: 19 and over
Trial IDs: 9846, NCI-2015-00863, P9846, P9846_R02PAPPHOLD01, NCT02474160
Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Recurrent or Progressive Germ Cell Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CCI-09-00196, NCI-2013-01195, NCT01270742
Convection-Enhanced Delivery of Anti-EGFRvIII Immunotoxin MR1-1 in Treating Patients With Residual, Progressive, or Recurrent Gliomas or Brain Metastases
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 00011617, NCI-2011-03834, NCT01009866
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients with CEA Positive Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: 14238, NCI-2014-02079, 116082, 14206, 14238/117640, NCT02293954
Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin C Followed by Standard Chemotherapy in Treating Patients With Peritoneal Carcinomatosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-09-332, NCI-2013-01214, 11-075, NCT02040142
Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448
Dexmedetomidine Hydrochloride in Reducing Pain in Patients Undergoing Thoracic Surgery
Phase: Phase III
Type: Supportive care
Age: 21 and over
Trial IDs: 13-163, NCI-2013-02150, NCT01973452
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 2012-0920, NCI-2013-02348, NCT01927731
Endoscopic Dilation With or Without Triamcinolone in Treating Patients With Anastomotic or Radiation Induced Difficulty Swallowing
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: MCC 17316, NCI-2013-01370, 13.05.0023, NCT01873573
Endoscopic Radiofrequency Ablation in Treating Patients With Malignant Biliary Obstruction
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-405, NCI-2012-00258, NCT01543607
Donor Cytomegalovirus-Specific Cytotoxic T Lymphocytes in Treating Patients Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00013947, NCI-2013-00579, NCT01274377
.
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients with a Persistent Cytomegalovirus Infection after Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2013-0657, NCI-2014-01990, NCT02210078
Donor Cytotoxic T Lymphocytes in Treating Cytomegalovirus Infection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: Not specified
Trial IDs: 12-086, NCI-2012-01238, NCT01646645
Donor Multi-virus-Specific Cytotoxic T Lymphocytes in Treating Epstein-Barr Virus, Cytomegalovirus, Adenovirus, Human Herpes Virus 6, and BK Virus Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: Not specified
Trial IDs: H-29966, NCI-2012-02979, ARMS, H-29966 ARMS, NCT01570283
Donor Multivirus-Specific T-Cells in Treating Patients with Persistent or Recurrent Viral Infections after Donor Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-33903, NCI-2014-00896, CHARMS, NCT02108522
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Inherited Metabolic Disorders
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 00015791,
NCI-2011-03853,
NCT01372228
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Severe Autoimmune Diseases
Phase: No phase specified
Type: Treatment
Age: 18 to 69
Trial IDs: Pro00010324,
NCI-2013-01245, NCT00849745
Donor Regulatory T Lymphocytes in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 18 to 70
Trial IDs: 17263, NCI-2014-01426, MCC-17263, NCT01795573
Donor Stem Cell Transplant after Busulfan and Fludarabine Phosphate with or without Anti-thymocyte Globulin in Treating Patients with Inherited Metabolic Disorders, Severe Osteopetrosis, or Rett Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 55 and under
Trial IDs: 2013LS104,
NCI-2014-02309, 1406M51542, MT2013-31, NCT02171104
Effect of Radiation on Bone in Patients with Cancer of the Sacrum
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 14-208,
NCI-2015-00893,
NCT02323295
Efficacy and Safety of Ferriprox(R) in Patients With Sickle Cell Disease or Other Anemias
Phase: Phase IV
Type: Treatment
Age: 2 and over
Trial IDs: LA38-0411,
NCI-2014-01229,
NCT02041299
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: CCSJ148X2201,
NCI-2015-00634, NCT02268526
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: MITO 02-03,
NCI-2012-00422, NCT00801086
Eligibility Screening and Research Sample Collection in Determining Patient Eligibility to Participate in Clinical Trials
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Health services research
Age: Not specified
Trial IDs: 01-C-0129,
NCI-2013-02022, 010129, 01-C-0129 M, NCT00026754
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15677,
NCI-2015-01298, 2015-000134-30, I5B-MC-JGDJ, NCT02451943
Acupuncture in Treating Chemotherapy-Induced Neuropathy in Cancer Survivors
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 and over
Trial IDs: 2013-0930,
NCI-2014-01466,
NCT02168894